Archive · 5 Aug 2025
Vertex Stock Drops After FDA Doubts and Drug Trial Failure
Vertex, a drug company, had a setback with its new pain medicine, Journavx.
The FDA, which approves drugs, isn't sure the drug can be used widely for long-term pain.
Also, another drug they were testing didn't work.
These issues caused the company's stock price to drop.
Vertex is still working on Journavx and is exploring its use for a specific type of nerve pain.
The company reported good earnings recently and is also changing its top scientist soon.
Vertex Pharmaceuticals' stock fell after FDA concerns regarding its pain drug, Journavx, for chronic pain.
The FDA staff indicated no path forward for broad use of Journavx in chronic pain treatment.
Vertex is developing Journavx as a non-opioid alternative and also studied other drugs like VX-993.
VX-993 failed in a mid-stage study for acute pain, leading Vertex to halt its development.
Despite setbacks, Vertex reported strong second-quarter results and announced a transition in its leadership.
- Who
- Vertex Pharmaceuticals and its pain drugs, as well as FDA.
- What
- Vertex Pharmaceuticals' stock fell due to FDA concerns and trial failures for pain drugs.
- When
- The stock dropped on Tuesday, after the FDA's concerns were announced.
- Where
- The US market.
- Why
- Due to the FDA's reservations about Journavx's broad use and VX-993 trial failure, impacting investor confidence.
Vertex Pharmaceuticals
FDA
Market Impact
Vertex Pharmaceuticals
The company is pushing for non-opioid treatments and pursuing further studies.
FDA
The FDA's stance reduces the potential for Vertex to capture the broadest chronic pain market.
- Company
- Vertex Pharmaceuticals Inc.
- Drug Name
- Journavx (pain drug)
- Stock drop
- Up to 14% in premarket trading
- Other drug
- VX-993 (experimental)
- FDA Stance
- No path forward for broad use of Journavx
- Leadership Change
- David Altshuler to retire and Mark Bunnage to take over